RecruitingPHASE1, PHASE2NCT07575919

Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL

Studying Lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Liping Dou
Intervention
CD22/CD19 Dual-Target CAR-T Cells(biological)
Enrollment
20 enrolled
Eligibility
18-85 years · All sexes
Timeline
20262027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07575919 on ClinicalTrials.gov

Other trials for Lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoma

← Back to all trials